Article
Eisai, Biogen's Alzheimer's drug price should not dent demand, analysts say
Rating:
0.0
Views:
59
Likes:
1
Library:
1
The $26,500-per-year price tag for Eisai Co Ltd and Biogen Inc's newly approved Alzheimer's disease drug is slightly above expectations, but should not dent demand for the promising therapy, Wall Street analysts said.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value